Compare Spotify Technology (SPOT) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Spotify Technology trades at $528.22 (market cap $108.22B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Spotify Technology is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spotify Technology for 111 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| SPOT | TAK | |
|---|---|---|
Market Cap | $108.22B | $58.74B |
Volume | 1,655,796 | 3,110,994 |
Sector | Media | Health |
52-Week High | $692.04 | $19.05 |
52-Week Low | $412.75 | $13.23 |
Typical Hold Time | 111 Days | 1 Days |
Enterprise Value | $98.23B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $529.14, up 3.16% with strong technical momentum above key support levels. The company demonstrates robust fundamental performance with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent earnings show mixed results with two beats and one miss, while analyst consensus remains strongly bullish with a $606.50 price target. Technical indicators show bullish moving averages but neutral oscillators, with RSI suggesting potential overbought conditions near-term.
Spotify presents a compelling growth story with expanding profit margins and strong cash flow generation. Key opportunities include continued subscriber growth and new monetization tools, while risks involve competitive pressures and execution challenges. The stock trades near the lower end of analyst targets, offering potential upside if execution continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
